Clinical trials: insulin glargine
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Primary objective: The primary objective of this trial is: To evaluate the efficacy of initiating Lantus in combination with oral antidiabetics drugs compared to oral antidiabetic treatment optimised by enhancing hygienic and…
- Trial name
- NCT00174681
- Testing
- Insulin Glargine
- Where
- 6 sites in Croatia, Czechia and 4 more
- Volunteers
- 390 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of…
- Trial name
- NCT02229227
- Testing
- Albiglutide, Insulin Glargine and Insulin Lispro
- Where
- 157 sites in United States, Brazil and 12 more
- Volunteers
- 814 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 2 diabetes…
- Trial name
- EDITION JP II (NCT01689142)
- Testing
- Insulin glargine new formulation (HOE901), Insulin glargine (HOE901)
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy
To compare the glycemic control, as measured by HbA1C, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin
- Trial name
- NCT00358124
- Testing
- insulin glargine, rosiglitazone, metformin
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Sanofi
Diabetes, Hyperglycemia
Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the…
- Trial name
- NCT00394407
- Testing
- sliding scale regular insulin, glargine basal insulin and glulisine prandial insulin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Emory University
Diabetes Mellitus Type 2
Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement
Primary objective: Difference in frequency of subjects with conventionally detected hypoglycemia by the subject [at least one measurement smaller/equal 60mg/dl documented in the 8-point profile in the case record form (CRF) or…
- Trial name
- SAFIR (NCT00354939)
- Testing
- Insulin glargine
- Volunteers
- 480 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood…
- Trial name
- EFFICACY (NCT00909480)
- Testing
- insulin detemir, insulin glargine
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 457 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Oral Anti Diabetic Agents in the Hospital
This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes…
- Trial name
- NCT04416269
- Testing
- Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin
- Where
- 3 sites in United States
- Volunteers
- 85 people
- Sponsor
- Emory University
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia.
- Trial name
- NCT01570751
- Testing
- insulin degludec, insulin glargine
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 145 people
- Sponsor
- Novo Nordisk A/S
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
- Trial name
- NCT06881264
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatogenous Diabetes
Human Versus Analogue Insulin in Patients After Pancreatectomy.
Pancreatectomy is a common treatment modality for both benign and malignant pathologies. One of the most common complications after pancreatectomy is pancreatogenous diabetes mellitus.
- Trial name
- NCT04690309
- Testing
- Treatment with human insulin preparations or treatment with insulin analogues
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Polish Society of Diabetology
Prediabetes, Type 2 Diabetes
RISE Pediatric Medication Study
The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell…
- Trial name
- RISE Peds (NCT01779375)
- Testing
- Metformin, Glargine
- Where
- 4 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- RISE Study Group
Type 2 Diabetes Mellitus
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Primary Objective: To assess the mean change in HbA1c (glycated haemoglobin). Secondary Objectives: To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of: Targeted HbA1c; Targeted fasting self…
- Trial name
- EASE (NCT02954692)
- Testing
- INSULIN GLARGINE (U300), metformin, sulfonylurea
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Sanofi
Diabetes, Hyperglycemia
Insulin Secretion in Diabetes Before and After Glycemic Control
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes.
- Trial name
- NCT00469833
- Testing
- insulin glargine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Hyperglycemia, Diabetes Mellitus
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of…
- Trial name
- GIH (NCT01810952)
- Testing
- Glargine insulin, Lispro insulin, NPH Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Baylor College of Medicine
Type 1 Diabetes
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
The Diabetes Interactive Diary (DID) is both a CHO (carbohydrates )/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional and patient by SMS…
- Trial name
- DID3 (NCT01192711)
- Testing
- Diabetes Interactive Diary (DID)
- Where
- 13 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Consorzio Mario Negri Sud
Diabetes
Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes
Long-acting insulin injected at bedtime may cause hypoglycemia (low blood sugar) in the night in patients with diabetes. The aims of the study are 1) to compare the dynamic characteristics of long-acting insulin analog glargine…
- Trial name
- ClampHOE901 (NCT00468364)
- Testing
- insulin glargine, NPH insulin
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- University of Giessen
Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Primary Objective: The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c)…
- Trial name
- NCT01476475
- Testing
- Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
- Where
- 70 sites in United States, Chile and 11 more
- Volunteers
- 323 people
- Sponsor
- Sanofi
Diabetes Mellitus
Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive.
- Trial name
- ktpump (NCT00574405)
- Testing
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute